Fresenius Investor Relations

🌍 After many conferences and investor meetings, we are now fully focused on preparing the Fresenius Q3/24 results, which we will publish on November 6. Therefore, our quiet period starts today until November 5. During this time we will not communicate externally. On November 6, we will be back with Fresenius Q3/24 results, business updates and more! First information can be found on our financial results page, including the webcast link for the Q3/24 conference call: https://lnkd.in/dfy49P5 We look forward to updating you again soon! #FreseniusResults #Fresenius_IR #FutureFresenius

Firsthand information is key when engaging with our stakeholders on our company’s progress and innovations! Last week, our IR team had the opportunity to visit the Helios University Hospital Wuppertal, gaining valuable insights into the drivers behind our Operating Company Fresenius Helios in Germany: its forward-looking clustering strategy and state-of-the-art technologies. It was truly inspiring to witness our medical teams utilizing the latest innovative tools during complex surgeries, and to see the construction work of the new facility firsthand. The new hospital building will set a new benchmark for medical quality and efficiency. A Big Thank You to the Helios teams for accompanying us through the day: Dr. Holger Raphael, Patrick H., Simone Hyun, Friedrich-Carl von Rundstedt, Janine von Heyking, Svenja Neuhaus, Marie Weidauer, Sandra Schütz, Tobias Wagner As part of #FutureFresenius, Helios continues to drive quality standards in specialized and patient-centered care! #HUKW #FreseniusHelios #CommittedToLife

Fantastic news from our Operating Company, Fresenius Kabi! We’ve entered into a development agreement with Cellular Origins to advance automation in cell and gene therapy manufacturing. This strong collaboration will help improve patient care with more precise, efficient, and automated production processes. Press Release: https://lnkd.in/eY6tWptr Brief News: https://lnkd.in/e7srEDn8 #CellTherapy #MedTech #FutureFresenius #CommittedToLife

Inspiring interview by our CEO Michael Sen, published in the Frankfurter Allgemeine Zeitung. Michael talks about #FutureFresenius, a plan that has worked and is unfolding increasingly momentum. Fresenius is now a more focused, simpler and stronger company. Furthermore Michael elaborates on growth opportunities offered by the use of AI in our business. #TeamFresenius #FutureFresenius #CommittedToLife

Fresenius continues to gain momentum with our #FutureFresenius strategy: Our Operating Company Fresenius Kabi just announced that the European Commission (EC) granted marketing authorization for FYB202, a biosimilar candidate to Stelara® (ustekinumab) indicated for the treatment of several serious inflammatory diseases. In February 2023, Fresenius Kabi entered into a global commercialization partnership with Formycon for the ustekinumab biosimilar candidate covering key global markets. Read more below! Press Release: https://lnkd.in/eEcjckBt Brief News: https://lnkd.in/eCtBX5KM #Biosimilars #Vision2026 #CommittedToLife

A very warm welcome to Nick S. who will join our team as Head of Investor Relations starting October 1, 2024. Nick is an internationally experienced healthcare and capital market expert, and we are looking forward to driving the #FutureFresenius momentum together with him! Our heartfelt thank you goes to Markus Georgi who is leaving the company after nine years to pursue new opportunities. Your leadership and dedication have significantly shaped our Investor Relations work. Thank you so much for your commitment and team spirit. We wish you all the best for your future endeavors! Investor News: https://lnkd.in/eV3zbRes #TeamFresenius #FutureFresenius #CommittedToLife

We just returned from the Bank of America's Global Healthcare Conference in London. This event was another great opportunity to engage with many investors and exchange on our strategic updates. Our day was packed with several group meetings and insightful discussions about our Operating Companies Fresenius Kabi and Helios. We liked the format and perfect organization of the event! We’re excited about the growing interest and confidence in our company and the structural progress that are driving performance. Thanks to Marianne B. and the whole BofA-Team. #Fresenius_IR #CommittedToLife

On today’s International Day of Democracy, democracy is under pressure. Established by the United Nations General Assembly in 2007, the International Day of Democracy invites all UN Member States to raise public awareness about democracy. In this spirit, I'd like to share some personal thoughts on the current state of democracy in the world and how it is inextricably linked to equitable healthcare. In recent years, democracy has increasingly come under pressure around the world. The Bertelsmann Stiftung’s Transformation Index 2024 lists more autocratic states than it does democratic ones. Of the 137 developing and emerging countries analyzed, only 63 remain democracies, while the number of autocracies has risen to 74. We cannot and must not ignore this detrimental development! This is particularly worrisome given the impact that the lack of democratic participation can have on the health of millions of people worldwide:   Recent studies have shown that democratic nations invest more in their healthcare systems, provide higher quality healthcare for their citizens, and are more likely to support universal health coverage than autocracies. As a result, people living in a democracy experience less health inequality. As a leading healthcare company, Fresenius Group promotes the transformation of global healthcare and is committed to global health equity. With our products and services, we want to provide as many people as possible with access to high-quality, equitable, and affordable healthcare. That’s why we signed the Zero Health Gaps Pledge of the Global Health Equity Network earlier this year. To achieve global health equity, the promotion of democratic structures and institutions is a vital element in strengthening the resilience of global health systems. Let’s use today’s International Day of Democracy to reflect on the achievements and benefits of democracy and to remind ourselves not to take it for granted. #DemocracyDay #HealthEquity #FutureFresenius #CommittedToLife 

Watch our CEO Michael Sen discussing the role of artificial intelligence in enhancing patient care in his recent WELT TV interview: https://lnkd.in/eP-3_dcs The interview is in German, but we have summarized some highlights in English below: AI will be a game changer in healthcare because… 💡 As a general-purpose technology, AI will accelerate advances in related fields such as biology and technology to serve better patient outcomes 💡 Diagnoses, therapies and follow-up care will be increasingly driven by data Looking at Fresenius: ✅ Our approach is ‘human to human’, empowered by AI ✅ Trust, especially in data processing, is critical in healthcare – which is why everything we do is grounded in our promise: #CommittedToLife! Find out more in the video! 

Next stop: USA!🌎 This week, we continued our investor meetings with a roadshow in Chicago, organized by Kepler Cheuvreux, and attended the Annual Global Healthcare Conference in New York, hosted by Morgan Stanley. Regular updates with US investors are key to us! It was great to meet many large long-term oriented investors in Chicago. The Morgan Stanley conference in New York has been one of our important events for many years and we’re looking forward to keep sharing our company’s progress in the #FutureFresenius transformation! A big thank you to our partners for the seamless organization! Take a look at our conference presentation here: https://lnkd.in/gVgza-U4 #Fresenius_IR #CommittedToLife